339 related articles for article (PubMed ID: 36806787)
21. Targeted/emerging therapies for metastatic non-small cell lung cancer.
Horn L
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):676-8. PubMed ID: 25995428
[TBL] [Abstract][Full Text] [Related]
22. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
Lambros L; Guibourg B; Uguen A
Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
[No Abstract] [Full Text] [Related]
23. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
[TBL] [Abstract][Full Text] [Related]
24. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
25. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
26. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
27. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A; Lopes AR; McCusker MG; Garrigues SG; Ricciardi GR; Arensmeyer KE; Scilla KA; Mehra R; Rolfo C
Curr Oncol Rep; 2020 Apr; 22(5):48. PubMed ID: 32296961
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Tan AC; Tan DSW
J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
[TBL] [Abstract][Full Text] [Related]
29. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
30. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract][Full Text] [Related]
31. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
32. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
Song Z; Su H; Zhang Y
Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
[TBL] [Abstract][Full Text] [Related]
33. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
[TBL] [Abstract][Full Text] [Related]
34. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
35. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Lamberti G; Andrini E; Sisi M; Rizzo A; Parisi C; Di Federico A; Gelsomino F; Ardizzoni A
Crit Rev Oncol Hematol; 2020 Dec; 156():103119. PubMed ID: 33053439
[TBL] [Abstract][Full Text] [Related]
36. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
37. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
38. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
Tarigopula A; Ramasubban G; Chandrashekar V; Govindasami P; Chandran C
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1288. PubMed ID: 32881404
[TBL] [Abstract][Full Text] [Related]
39. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
40. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Nishimura T; Nakamura H
Adv Exp Med Biol; 2016; 926():115-137. PubMed ID: 27686809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
